Rezaltas is a combination drug featuring the Daiichi Sankyo-developed olmesartan medoxomil (Olmetec), a high-affinity ARB (angiotensin receptor blocker) and azelnidipine (Calblock), a long-acting CCB (calcium channel blocker) that the company researched and developed with Ube
Industries.
Daiichi Sankyo has claimed that it has combined olmesartan medoxomil, which has proven exceptionally powerful in lowering blood pressure among ARBs, with azelnidipine, a CCB that delivers ongoing decreases in blood pressure while minimizing sympathomimetic hyperactivity.
Daiichi Sankyo said that the clinical studies demonstrated that Rezaltas consistently suppresses blood pressure for 24 hours while offering excellent tolerance.